These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23922505)

  • 21. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
    Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
    Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome.
    Khalilian A; Ahmadimoghaddam D; Saki S; Mohammadi Y; Mehrpooya M
    Biopsychosoc Med; 2021 Feb; 15(1):3. PubMed ID: 33536043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitory effect of the selective serotonin 5-HT₃ receptor antagonist ramosetron on duodenal acidification-induced gastric hypersensitivity in rats.
    Nakata-Fukuda M; Hirata T; Keto Y; Yamano M; Yokoyama T; Uchiyama Y
    Eur J Pharmacol; 2014 May; 731():88-92. PubMed ID: 24632457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
    Andresen V; Montori VM; Keller J; West CP; Layer P; Camilleri M
    Clin Gastroenterol Hepatol; 2008 May; 6(5):545-55. PubMed ID: 18242143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
    De Ponti F; Tonini M
    Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
    Rao S; Lembo AJ; Shiff SJ; Lavins BJ; Currie MG; Jia XD; Shi K; MacDougall JE; Shao JZ; Eng P; Fox SM; Schneier HA; Kurtz CB; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1714-24; quiz p.1725. PubMed ID: 22986440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
    Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
    J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
    Tegaserod Clinical Research Group
    Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-irritable Bowel Syndrome Syrup Improves Constipation-Predominant Irritable Bowel Syndrome: A Randomized, Placebo-Controlled Trial.
    Pazhouh HK; Hosseini SMA; Taghipour A; Hamedi S; Noras M
    Chin J Integr Med; 2020 Oct; 26(10):729-735. PubMed ID: 32623701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotonin (5-HT3) receptor antagonists for the reduction of symptoms of low anterior resection syndrome.
    Itagaki R; Koda K; Yamazaki M; Shuto K; Kosugi C; Hirano A; Arimitsu H; Shiragami R; Yoshimura Y; Suzuki M
    Clin Exp Gastroenterol; 2014; 7():47-52. PubMed ID: 24648748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
    Funatsu T; Takeuchi A; Hirata T; Keto Y; Akuzawa S; Sasamata M
    Eur J Pharmacol; 2007 Nov; 573(1-3):190-5. PubMed ID: 17658508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review.
    Binienda A; Storr M; Fichna J; Salaga M
    Curr Drug Targets; 2018; 19(15):1774-1781. PubMed ID: 29284389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serotonin receptor modulators in the treatment of irritable bowel syndrome.
    Fayyaz M; Lackner JM
    Ther Clin Risk Manag; 2008 Feb; 4(1):41-8. PubMed ID: 18728719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-marketing Re-evaluation of Tongxiening Granules () in Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Multi-center, Randomized, Double-Blind, Double-Dummy and Positive Control Trial.
    Tang XD; Zhang SS; Hou XH; Li ZH; Chen SN; Feng PM; Yang XN; Li HZ; Wu JQ; Xia PJ; Yang XJ; Zhou HJ; Wang HY; Ai YW; Li K
    Chin J Integr Med; 2019 Dec; 25(12):887-894. PubMed ID: 31292845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
    Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
    Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
    Chey WD; Lembo AJ; Rosenbaum DP
    Am J Gastroenterol; 2017 May; 112(5):763-774. PubMed ID: 28244495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
    Gershon MD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.